GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (FRA:52U) » Definitions » Retained Earnings

Hyloris Pharmaceuticals (FRA:52U) Retained Earnings : €-80.76 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Hyloris Pharmaceuticals's retained earnings for the quarter that ended in Dec. 2023 was €-80.76 Mil.

Hyloris Pharmaceuticals's quarterly retained earnings declined from Dec. 2022 (€-65.38 Mil) to Jun. 2023 (€-70.88 Mil) and declined from Jun. 2023 (€-70.88 Mil) to Dec. 2023 (€-80.76 Mil).

Hyloris Pharmaceuticals's annual retained earnings declined from Dec. 2022 (€-65.38 Mil) to Dec. 2023 (€-80.76 Mil) and declined from Dec. 2023 (€-80.76 Mil) to Dec. 2024 (€-86.47 Mil).


Hyloris Pharmaceuticals Retained Earnings Historical Data

The historical data trend for Hyloris Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Retained Earnings Chart

Hyloris Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
Get a 7-Day Free Trial Premium Member Only -43.23 -54.81 -65.38 -80.76 -86.47

Hyloris Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -59.75 -65.38 -70.88 -80.76 -86.47

Hyloris Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Hyloris Pharmaceuticals  (FRA:52U) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Hyloris Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain with various other products in the pipeline. Its revenue is mainly generated in the United States.

Hyloris Pharmaceuticals Headlines

No Headlines